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Abstract
Background: Cancer is the leading cause of premature death in Canada. In the last decade, important gains in
cancer survival have been achieved by advances in adjuvant treatment. However, many oncologic treatments also
result in cardiovascular "toxicity". Furthermore, cardiac risk factors such as hypertension, dyslipidemia, and diabetes
mellitus are known to contribute to the progression of cardiac damage and clinical cardiotoxicity. As such, for many
survivors, the risk of death from cardiac disease exceeds that of recurrent cancer. While provision of care by
multidisciplinary teams has been shown to reduce mortality and hospitalizations among heart failure patients, the
effect of assessments and interventions by multidisciplinary specialists in cancer patients receiving cardiotoxic
chemotherapy regimens is currently unknown. Accordingly, we will examine the effect of a multi-disciplinary team
interventions in the early assessment, identification and treatment of cardiovascular risk factors in cancer patients
receiving adjuvant systemic therapy. Our main hypothesis is to determine if the incidence of LV dysfunction in
cancer patients undergoing adjuvant therapy can be reduced through a multidisciplinary team approach.
Methods/design: This is a randomized study comparing intensive multidisciplinary team intervention to usual care
in the prevention of LV remodeling in patients receiving anthracycline or trastuzumab-based chemotherapy. Main
objectives include early detection strategies for cardiotoxicity using novel biomarkers that reflect myocardial injury,
remodeling and/or dysfunction; early identification and intensive treatment of cardiovascular risk factors; and early
intervention with supportive care strategies including nutritional and pharmacist counselling, exercise training and
cardiology team support. Secondary objectives include correlation of novel biomarkers to clinical outcomes;
correlation of multidisciplinary interventions to adverse clinical outcomes; relationship of multidisciplinary
interventions and chemotherapy dose density; preservation of lean muscle mass; and patient reported outcomes
(symptom intensity and quality of life).
Discussion: Cardiac toxicity as a result of cancer therapies is now recognized as a significant health problem of
increasing prevalence. To our knowledge, TITAN will be the first randomized trial examining the utility of
multidisciplinary team care in the prevention of cardiotoxicity. We expect our results to inform comprehensive and
holistic care for patients at risk for negative cancer therapy mediated sequelae.
Trial registration: ClinicalTrials.gov, NCT01621659 Registration Date 4 June 2012.
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Background
As a result of improved anti-cancer therapies, many
patients now experience long-term survival after treat-
ment. However, cardiac toxicity of cancer therapy is
increasingly recognized as a major risk, such that for
many survivors, the risk of death from cardiac disease
exceeds that of recurrent cancer [1]. Negative lifestyle
behaviors not only account for at least of 30 % of cancer
deaths, but are well established causative factors for
cardiovascular disease. Overweight/obesity, low fruit and
vegetable intake coupled with high fat diet, physical
inactivity, smoking and alcohol use are firmly established
cancer-promoting, modifiable behaviors [2]. On this
background of significant baseline cardiovascular risk,
the ‘multiple-hits’ to the cardiovascular system with
adjuvant chemotherapy convey varying degrees of dir-
ectly negative effects [3]. Therefore, there is urgent need
for effective interventions in this population.
The most common manifestation of cardiotoxicity during
or after cancer therapy is left ventricular (LV) dysfunction
and heart failure (HF) [4]. Cancer therapy-associated
toxicity has been proposed to occur acutely (during
infusion), early (within the first year of therapy) and chronic
(>1 year post-therapy) [4]. Limat observed early and
frequent cardiotoxicity in 135 consecutive lymphoma
patients treated with CHOP (cyclophosphamide, doxorubi-
cin, vincristine prednisone) [5]. Twenty-seven (20 %)
patients suffered from a cardiac event within 1 year of treat-
ment; among these, 14 patients had clinical signs of HF
attributable to anti-cancer therapy. Long-term follow-up of
patients after anthracycline-based therapies demonstrated
abnormal cardiac function present in 18 % of patients
followed up for less than 10 years and in 38 % of those
followed for 10 years or more (median, 12 years) [6]. In 141
lymphoma patients assessed at least 5 years post-
chemotherapy, Hequet observed subclinical cardiomyop-
athy in 39 (27.6 %) using echocardiography; associated risk
factors included male gender, older age, and overweight [7].
Only 8 of these 39 patients received a doxorubicin dose >
300 mg/m2, indicating that even conservative doxorubicin
dosing conveys long-term cardiac sequelae. These observa-
tions herald an emerging and potentially devastating health
issue, as 60,000 patients per year are exposed to anthracy-
clines in the United States alone [8]. Maximizing the
benefits and minimizing negative cardiac effects of
anthracycline-based therapy is challenging. If cardiotoxicity
is observed then anti-cancer treatment may be decreased
or discontinued, potentially impacting remission rates [3].
Therefore, new approaches in early prevention and treat-
ment of anthracycline-induced cardiotoxicity are required.
Our group has observed high prevalence and negative
influence of cardiovascular risk factors in breast cancer
patients. In 41 breast cancer patients who had received
trastuzumab-based chemotherapy, we showed that at
~20 months following completion of therapy survivors
consistently had higher rates of cardiovascular risk
factors. Here, higher rates of overweight/obesity, low
cardiorespiratory fitness (VO2peak) and unfavorable lipid
profiles were observed compared to controls [9]. In 47
women who had received chemotherapy and endocrine
therapy for hormone-receptor positive breast cancer, we
again found consistently less favorable cardiovascular
risk factors compared to controls. Higher resting heart
rate and systolic blood pressure were observed; peak
exercise output, stroke volume and cardiac power output
were significantly lower in patients than controls [10].
While the cross-sectional designs limit our understand-
ing of baseline characteristics, these results consistently
identify significant clinical and sub-clinical negative
cardiovascular effects of anti-cancer therapy. The major
modifiable risk factors for cardiovascular disease (CVD)
are well-established, and include tobacco use, high blood
pressure (BP), high cholesterol, alcohol use, obesity and
physical inactivity. Unfortunately, in oncology trials
these risk factors have, to date, not been systematically
examined. Retrospective reviews indicate modifiable
cardiovascular risk factors including hypertension and cor-
onary artery disease predict development of anthracycline-
related cardiomyopathy [11, 12]. In patients receiving
trastuzumab in the adjuvant setting, hypertension and high
body mass index are associated with cardiac dysfunction
[13, 14]. Taken together, research examining early identifi-
cation of modifiable cardiovascular risk factors and
intensive management to prevent negative sequelae is
urgently required.
Importantly, LV dysfunction is now recognized as a
late effect of chemotherapy, not detectable until signifi-
cant damage has already occurred [15]. Unfortunately,
when cardiotoxicity is detected, cardiology services are
consulted late, if at all, and improvement in clinical
cardiac outcomes is not always possible. In women
receiving anthracycline-based chemotherapy, Cardinale
showed a four-fold decrease in the chance of complete
recovery from cardiac dysfunction for each doubling in
time-to-heart failure treatment [16], emphasizing the
urgency for early monitoring and intervention. Of note,
the cardinal symptoms of HF (dyspnea, fatigue and
edema) are common in cancer patients [17, 18], with
70–100 % reporting exercise intolerance and fatigue
[19], and are difficult for the practitioner to distinguish
from cardiac causes. Additionally, regular symptom
inquiry [20, 21], routine vital sign measurements, and
identification or management of cardiac risk factors
[22, 23] are not routinely attended to in the oncology
outpatient clinic. Taken together, these findings emphasize
the importance of careful screening, early identification
and intensive management of toxicities to ensure both ad-
equate anti-cancer treatment is delivered on schedule and
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full dose, and that acute/chronic cardiovascular morbidity
is prevented.
Patients at risk for or with cancer treatment-related
cardiac effects are complex, multi-disease patients requir-
ing multiple specialists [24], therefore, coordination of care
by both cardiology and oncology specialties is urgently
required. However, multiple challenges face clinicians man-
aging this patient population including lack of: risk-
stratification guidelines, distinguishing early toxicities,
evidence-based cardiovascular monitoring schedules, and
level 1 evidence for interventions. Furthermore, validation
of new imaging techniques and improved biomarkers are
necessary to individualize and monitor treatment.
Our main hypothesis is to determine if the incidence of
LV dysfunction in cancer patients undergoing adjuvant
therapy can be reduced through a multidisciplinary team
(MDT) approach
The main objectives include implementation of early detec-
tion strategies for cardiotoxicity with sensitive imaging
modalities; early identification and intensive treatment of
cardiovascular risk factors; and early intervention with
supportive care strategies including nutritional counselling,
pharmacist support, exercise training and cardiology team
support. Secondary objectives include correlation of novel
biomarkers to clinical outcomes; correlation of MDT inter-
ventions to adverse clinical outcomes; relationship of MDT
interventions and chemotherapy dose density; preservation
of lean muscle mass; and patient reported outcomes (symp-
tom intensity and quality of life).
Methods/design
TITAN (multidisciplinary Team IntervenTion in cArdio-
oNcology) is a randomized study comparing intensive
multidisciplinary team intervention to usual care in the
prevention of LV remodeling in patients receiving
anthracycline or trastuzumab-based chemotherapy. Add-
itional inclusion requirements are shown in Table 1.
Methods
The TITAN study underwent full Board review and was
approved by the University of Alberta Health Research
Ethics Board—Biomedical Panel. Potential participants
are consecutively identified at Tumor Board review of all
newly diagnosed cases of early breast cancer and lymph-
oma scheduled for chemotherapy (anthracycline and/or
trastuzumab-based). Following primary oncologist ap-
proval, a study coordinator provides potential partici-
pants with an overview of the study and written
information. Written informed consent to participate in
the TITAN study is obtained from all participants. After
informed consent, participants are scheduled for a
baseline clinic visit for final determination of eligibility.
Clinical assessments include physical examination,
cardiovascular history, symptomatology and risk factor
profile. Smoking status, vital signs, menstrual status,
weight and height will acquired. Cardiac MRI, coronary
artery calcium score (cardiac CT) and body composition
(Dual Energy X-ray Absorptiometry, or DEXA) will be
acquired. Maximal aerobic capacity (peak pulmonary
oxygen uptake or VO2peak) is evaluated with an incre-
mental exercise test; continuous expired gas analysis is
performed with a metabolic measurement system. Heart
rate and cuff blood pressure are measured at each stage;
the highest oxygen consumed over 1-min will be used as
the peak VO2 score [25, 26]. Upper and lower extremity
maximal strength testing is also assessed. Detailed range
of motion assessments are performed by an expert
physiotherapist. In addition to clinically indicated labora-
tory, brain natriuretic protein, high-sensitivity troponin
and research biofluids (collagen remodeling products,
urine) are collected. Fasting lipid profile will be collected
at baseline. Total energy expenditure and activity energy
expenditure are evaluated with a SenseWear armband,
worn by the participant for 4 days [27]. Quality of life
will be assessed with instruments validated in cancer
populations (‘Screening for Distress’ [28] and MDASI-
HF [29], both based on the Edmonton Symptom Assess-
ment System [30]). Each assessment will occur at
baseline, 6 and 12 months. Our primary outcome is
measure of left ventricular ejection fraction at 12 months.
After baseline assessments, participants will be
randomized 1:1 to multidisciplinary intervention or usual
care (Fig. 1)
Group 1: Multidisciplinary Team Intervention
Patients randomized to the MDT arm will be assessed
by the cardio-oncology team, and receive regular
clinical assessment. Blood pressure and lipid profile
targets will be guided by national guideline consensus
Table 1 Inclusion and Exclusion Criteria
Inclusion criteria Exclusion criteria
• Patients receiving anthracycline
or trastuzumab-based
chemotherapy.
• Histologically confirmed malignancy;
• Age > 18 years, and
• No contraindication to MRI.
• Physical disability
preventing exercise
testing or DEXA scan;







or baseline LV ejection
fraction less than 50 %;
• Previous anthracycline or
trastuzumab-based therapy;
• Previous radiotherapy to
thorax.
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documents [31, 32]. Counselling and written information
regarding optimal nutrition will be provided by a
registered dietician. As indicated, a clinical pharmacist will
offer ongoing monitoring and support of any prescribed
medications. Patients will be encouraged to participate in
a supervised exercise training program consisting of
endurance and resistance training twice per week and
unsupervised endurance exercise (walking and/or cycling)
exercise training another 1–2 days per week. During the
first 3–4 months, moderate-intensity continuous aerobic
training (30 to 60 min at 60 to 80 % peak VO2) will be
performed on a cycle ergometer or treadmill. Thereafter,
participants will perform moderate intensity contimuous
exercise (1 day/week) and high-intensity aerobic interval
training. Participants will also perform 1–3 sets of
moderate upper (bench press, lattissimus dorsi puldown,
shoulder press, arm curl and tricep extension) to lower
extremity (leg press, leg extension and leg curl) resistance
training (10 to 15 repetitons with weight added after 3
sets are completed while adhering to strict technique).
All subjects will be given an exercise diary to record
exercises performed, training heart rate, weight lifted and
rate of perceived exertion.
Group 2: Usual Care
Patients randomized to usual care will receive standard
anti-cancer therapy and standard clinical monitoring.
Blinding and masking
The exercise assessments (baseline, 6 months and 1 year)
are performed at a different facility by different staff than
the supervised exercise training team. The cardiac MRI
interpreter is blinded to the group assignment.
Sample size calculations
The incidence of left ventricular systolic dysfunction in
early breast cancer patients receiving trastuzumab has
been reported as approximately 10 % in randomized
clinical trials [33] and up to 22 % in non-trial commu-
nity based practice [34]. The 1 year incidence of left
ventricular dysfunction of early breast cancer patients
receiving anthracyclines is not well characterized. In a
randomized, placebo controlled trial on the prevention
of cardiotoxicity of cancer patients receiving high dose
anthracyclines, the incidence of LV dysfunction at 1 year
was 43 % in the control arm vs. 0 % in the treatment
arm [35]. Extrapolating from these results, we estimate
that the 1 year incidence of left ventricular systolic
dysfunction in our combined cohort of patients receiving
trastuzumab and/or anthracyclines will be 15 % in those
patients receiving usual care. Patients will be analyzed
on an intent-to-treat basis. For patients attending the
multidisciplinary clinic and receiving early pharmaco-
logic intervention, we estimate the 1 year incidence of
LV systolic dysfunction at 5 %. Given the high accuracy
and reproducibility of cardiac MRI [36], with a two
tailed significance level ∞ = 0.05 and power = 0.80 then
36 participants are required in each group. We
anticipate a 10 % drop-out rate and a 3 % mortality
during the 1 year follow-up so aim to recruit 40 patients
in each arm.
Data management
Study data are collected and managed using REDCap
electronic data capture tools hosted at the University of
Alberta [37]. REDCap (Research Electronic Data Capture)
Fig. 1 Flow chart TITAN Study
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is a secure, web-based application designed to support data
capture for research studies, providing 1) an intuitive inter-
face for validated data entry; 2) audit trails for tracking data
manipulation and export procedures; 3) automated export
procedures for seamless data downloads to common statis-
tical packages; and 4) procedures for importing data from
external sources. Research biospecimens are stored within
the Alberta Cancer Research Biobank [38] and maintained
according to established standard operating procedures.
Safety
Maximal exercise testing is safe for patients with early and
metastatic cancer; the exercise protocol in this study has
been used in healthy older subjects, cardiac patients and
breast cancer survivors [10, 25, 26]. Participants experience
normal effects of maximal exercise testing including sore
muscles and temporary post-exercise fatigue.
Discussion
Cardiac toxicity as a result of cancer therapies is now
recognized as a significant health problem of increasing
prevalence. Not only deleterious cardiac effects, but
negative impacts on the entire oxygen cascade and
multiple organ systems highlight the need for multiple
interventional approaches as we will undertake here. To
our knowledge, TITAN is the first randomized trial
examining the effect of multidisciplinary team interven-
tions in the prevention of chemotherapy-related cardio-
toxicity. We expect that, in the short-term, this study
will find that early multidisciplinary care will maintain
cardiac geometry and enhance patient-reported quality
of life. In the long-term, we anticipate that early
supportive care interventions will prevent deleterious
cardiovascular effects of cancer treatment, and improve
overall survival (both cancer and cardiovascular). We
also expect this work to inform new approaches in the
delivery of comprehensive and holistic care in patients at
risk for cancer therapy-mediated cardiovascular toxicity.
Conclusion
Patients at risk for or with cancer treatment-related cardiac
effects are complex, multi-disease patients requiring mul-
tiple specialists. The TITAN Study will provide high-level
evidence in the development of guidelines for multidiscip-
linary preventive initiatives, locally, nationally and inter-
nationally. Lastly, this work will inform and support other
long-term goals of our cardio-oncology team, in the
prevention, detection and treatment of cardiovascular
effects of cancer therapies.
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